B+
Bull case
0%
Probability
Target price
$235.00
-1.8% vs current
UFPT
UFPCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$198.00
-17.3% vs current
B-
Bear case
0%
Probability
Target price
$160.00
-33.1% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-30.2
Negative
Company
-
Unavailable
Macro
-30.2
Negative
Pulse
-
Unavailable
Sentiment proxy
+32.2
Score
AI commentary
UFPT screens as a cautious monitoring name rather than a high-conviction long. Primary sources support a credible medtech CDMO story with real customer relationships, contract extensions, and 2026 capacity adds, but the current setup still needs proof that acquisition-led growth is turning into cleaner organic acceleration and margin recovery. With neutral deterministic priors and only moderate evidence quality, the balance looks more hold/watch than fresh upside chase.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06catalystQ1 2026 print must confirm that 2025 execution drags are fadingHigh impact
The key near-term check is whether UFPT converts its strong medtech demand into cleaner margins after 2025 absorbed about $6.3 million of AJR labor inefficiencies, with the Q4 impact already down to $1.2 million; a solid Q1 would support the view that the 2025 drag was temporary rather than structural [#10-K-2026-02-27].
2026-06-04eventJune 4, 2026 CEO transition is a real governance checkpointMedium impact
Jeffrey Bailly is scheduled to retire as CEO at the June 4, 2026 annual meeting, with President Mitchell Rock set to assume the role while Bailly remains executive chairman for one year; a smooth handoff would reinforce continuity, while any signs of disruption could compress the premium multiple [#PR-2025-12-02].
2026-12-31catalystDominican Republic capacity adds and customer program ramps are the main 2026 upside leverHigh impact
Management said 2025 results included a contract extension with its largest customer through 2029, added volumes and a new program in La Romana, and a planned new Santiago facility in Q2 2026 to localize and ramp a third major Safe Patient Handling program; if these ramps translate into sustained organic acceleration, the stock can work, but that proof is still ahead [#10-K-2026-02-27] [#8-K-2026-02-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology